Program
Epinephrine
Also written as “epinephrine inhalation aerosol”, “Epinephrine Nasal Spray, 2.5 mg” and “Epinephrine Nasal Spray, 5.25 mg”.
Its studies are mostly in Anaphylaxis · Asthma · Hypersensitivity · Chronic Urticaria · Respiratory Tract Infections, led by 7 companies.
Drug pageEpinephrine: every studyMany companies study it; this page follows only the 16 they lead. All 221 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amphastar Pharmaceuticalsits history only | 40 open or running | phase 4since Dec 19, 2019 | Jun 7, 2010 | none ahead |
| Nasus Pharmaits history only | 42 open or running | phase 3since Jun 8, 2025 | Dec 1, 2020 | none ahead |
| ARS Pharmaceuticalsits history only | 32 open or running | phase 4since Feb 18, 2025 | Jun 9, 2021 | Apr 2027phase 4 · NCT06834165 |
| De Motu Cordisits history only | 20 open or running | phase 1since Nov 9, 2021 | Nov 9, 2021 | none ahead |
| ALK-Abellóits history only | 10 open or running | phase 4since Jun 20, 2013 | Jun 20, 2013 | none ahead |
| Hikma Pharmaceuticalsits history only | 11 open or running | phase 2since Aug 18, 2026 | Aug 18, 2026 | May 8, 2027phase 2 · NCT07891780 |
| Smith & Nephewits history only | 10 open or running | phase 2since Apr 5, 2017 | Apr 5, 2017 | none ahead |
Also a collaborator on its studies: Medistat Ltd., Israel, Pharma Medica Research and Novotech (Australia) Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jun 7, 2010.
- Nov 15, 2011Phase 3 study in AsthmaAmphastar Pharmaceuticals · NCT01476904 · 208 enrolled · United States
- Jun 20, 2013ALK-Abelló’s first study: phase 4 study in Handling of Auto-injectorsNew to ALK-AbellóALK-Abelló · NCT01887405 · 91 enrolled · Sweden
- Apr 5, 2017Smith & Nephew’s first study: phase 2 study in Healthy VolunteerNew to Smith & NephewSmith & Nephew · NCT03119181 · 40 enrolled · United States
- Dec 19, 2019Phase 4 study in AsthmaAmphastar Pharmaceuticals · NCT04207840 · 28 enrolled · United States
- Dec 1, 2020Nasus Pharma’s first study: phase 1 study in AnaphylaxisNew to Nasus PharmaNasus Pharma · NCT04696822 · 12 enrolled · Israel
- Jun 9, 2021ARS Pharmaceuticals’ first study: phase 1 study in Respiratory Tract InfectionsNew to ARS PharmaceuticalsARS Pharmaceuticals · NCT04930900 · 15 enrolled · Australia
- Nov 9, 2021De Motu Cordis’s first study: phase 1 study in AnaphylaxisNew to De Motu CordisDe Motu Cordis · NCT05152901 · 23 enrolled · Australia
- Aug 22, 2023Phase 1 study in AnaphylaxisDe Motu Cordis · NCT06013150 · 24 enrolled · Australia
- Dec 18, 2023Phase 2 study in AnaphylaxisNasus Pharma · NCT06205134 · 12 enrolled · Israel
- Feb 18, 2025Phase 4 study in HypersensitivityARS Pharmaceuticals · NCT06834165 · 600 planned · United States
- Apr 4, 2025Phase 2 study in Chronic UrticariaARS Pharmaceuticals · NCT06927999 · 42 planned · United States, Germany
- Jun 8, 2025Phase 3 study in Anaphylaxis FoodNasus Pharma · NCT07045701 · 30 planned · Israel
- Nov 6, 2025Phase 2 study in AnaphylaxisNasus Pharma · NCT07228325 · 50 planned · Canada
- Aug 18, 2026Hikma Pharmaceuticals’ first study: phase 2 study in Hypersensitivity, ImmediateNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT07891780 · 44 planned · United States
Ahead
- Apr 2027Primary completion: phase 4 study in HypersensitivityARS Pharmaceuticals · NCT06834165
- May 8, 2027Primary completion: phase 2 study in Hypersensitivity, ImmediateHikma Pharmaceuticals · NCT07891780
- Jun 2027Primary completion: phase 2 study in Chronic UrticariaARS Pharmaceuticals · NCT06927999
TargetBeta
“Adrenergic receptor agonist; Adrenergic receptor agonist”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07891780Hypersensitivity, Immediate · United States | 2 | Not yet recruiting | Hikma Pharmaceuticals | May 8, 2027 | 44 |
| NCT07228325Anaphylaxis · Canada | 2 | By invitation | Nasus Pharma | Mar 2026 | 50 |
| NCT07045701Anaphylaxis Food · Israel | 3 | By invitation | Nasus Pharma | Jun 12, 2026 | 30 |
| NCT06927999Chronic Urticaria · United States, Germany | 2 | Recruiting | ARS Pharmaceuticals | Jun 2027 | 42 |
| NCT06834165Hypersensitivity · United States | 4 | Recruiting | ARS Pharmaceuticals | Apr 2027 | 600 |
| NCT06205134Anaphylaxis · Israel | 2 | Completed | Nasus Pharma | Feb 2, 2024 | 12 |
| NCT06013150Anaphylaxis · Australia | 1 | Completed | De Motu Cordis | Dec 15, 2023 | 24 |
| NCT05152901Anaphylaxis · Australia | 1 | Completed | De Motu Cordis | Jun 6, 2022 | 23 |
| NCT04930900Respiratory Tract Infections · Australia | 1 | Completed | ARS Pharmaceuticals | Mar 31, 2022 | 15 |
| NCT04696822Anaphylaxis · Israel | 1 | Completed | Nasus Pharma | Sep 28, 2021 | 12 |
| NCT04207840Asthma · United States | 4 | Completed | Amphastar Pharmaceuticals | Dec 20, 2019 | 28 |
| NCT03119181Healthy Volunteer · United States | 2 | Completed | Smith & Nephew | May 11, 2017 | 40 |
| NCT01887405Handling of Auto-injectors · Sweden | 4 | Completed | ALK-Abelló | Sep 2012 | 91 |
| NCT01476904Asthma · United States | 3 | Completed | Amphastar Pharmaceuticals | Apr 2012 | 208 |
| NCT01357642Asthma · United States | 3 | Completed | Amphastar Pharmaceuticals | Nov 2011 | 373 |
| NCT01143051Asthma · United States | 2 | Completed | Amphastar Pharmaceuticals | Jun 2010 | 24 |
How it is read
Names in the registry
- “epinephrine inhalation aerosol”, 4 entries
- “Epinephrine Nasal Spray, 2.5 mg”, 1 entry
- “Epinephrine Nasal Spray, 5.25 mg”, 1 entry
- “0.5 mg epinephrine”, 1 entry
- “1 mg epinephrine”, 1 entry
Codes read as this program: FMXIN002.
Conditions, from the studies’ own filings
- Anaphylaxis, 7 studies
- Asthma, 4 studies
- Hypersensitivity, 2 studies
- Chronic Urticaria, 1 study
- Respiratory Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.